The role of MEK inhibitors in the treatment of metastatic melanoma

Current Opinion in Oncology

Volumn 26, Issue 2, 2014, Pages 196-203

  Grimaldi, Antonio M ^a   Simeone, Ester ^a   Ascierto, Paolo A ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

BRAF; MAPK pathway; MEK inhibitors; Metastatic melanoma; NRAS

Indexed keywords

GTP PHOSPHOHYDROLASES; HUMANS; MAP KINASE KINASE 1; MELANOMA; MEMBRANE PROTEINS; MUTATION; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; TREATMENT OUTCOME;

EID: 84894041494     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000050     Document Type: Review

References (56)

1. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 410:37-40
2. Liebmann C. Regulation of MAP kinase activity by peptide receptor signalling pathway: Paradigms of multiplicity. Cell Signal 2001; 13:777-785
3. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135-2147
4. Goel VK, Lazar AJ, Warneke CL, et al. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol 2006; 126:154-160
5. Röring M, Brummer T. Aberrant B-Raf signaling in human cancer-10 years from bench to bedside. Crit Rev Oncog 2012; 17:97-121
6. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954
7. Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic BRaf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008; 105:3041-3046
8. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006; 439:358-362
9. Bedogni B, Welford SM, Kwan AC, et al. Inhibition of phosphatidylinositol-3-kinase and mitogen-Activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPR as mouse model. Mol Cancer Ther 2006; 5:3071-3077
10. Thompson N, Lyons J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 2005; 5:350-356
11. Hsueh C-T, Liu D, Wang H. Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials. Biomarker Res 2013; 1:1
12. Favata MF, Horiuchi KY, Manos EJ, et al. Identification of a novel inhibitor of mitogen-Activated protein kinase kinase. J Biol Chem 1998; 273:18623-18632
13. Yamaguchi T, Kakefuda R, Tajima N, et al. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol 2011; 39:23-31
14. Gilmartin AG, Bleam MR, Groy A, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011; 17:989-1000
15. Infante JR, Fecher LA, Falchook GS, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: A phase 1 dose-escalation trial. Lancet Oncol 2012; 13:773-781
16. Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013; 31:482-489
17. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367:107-114
18. Ascierto PA, Minor D, Ribas A, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013; 31:3205-3211
19. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-Activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008; 26:2139-2146
20. Bennouna J, Lang I, Valladares-Ayerbes M, et al. A phase II, open-label, randomized study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs 2011; 29:1021-1028
21. Bodoky G, Timcheva C, Spigel DR, et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs 2012; 30:1216-1223
22. Hainsworth JD, Cebotaru CL, Kanarev V, et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with nonsmall cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol 2010; 5:1630-1636
23. Hayes DN, Lucas AS, Tanvetyanon T, et al. Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res 2012; 18:2056-2065
24. Kirkwood JM, Bastholt L, Robert C, et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012; 18:555-567
25. O'Neil BH, Goff LW, Kauh JS, et al. Phase II study of the mitogen activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2011; 29:2350-2356
26. Catalanotti F, Solit DB, Pulitzer MP, et al. Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/Kmutated melanoma. Clin Cancer Res 2013; 19:2257-2264
27. Robert C, Dummer R, Gutzmer R, et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: A phase 2 double-blind randomised study. Lancet Oncol 2013; 14:733-740
28. Schad K, Baumann Conzett K, Zipser MC, et al. Mitogen-Activated protein/ extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clin Cancer Res 2010; 16:1058-1064
29. No authors listed]. Selumetinib shows promise in metastatic uveal melanoma. Cancer Discov 2013; 3:OF8
30. Winski S, Anderson D, Bouhana K, et al. MEK162 (ARRY-162), a novel MEK 1/2 inhibitor, inhibits tumor growth regardless of KRas/Raf pathway mutations. Proceedings of the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; Berlin, Germany 2010
31. Bendell JC, Papadopoulos K, Jones SF, et al. A phase I dose-escalation study of MEK inhibitor MEK162 (ARRY-438162) in patients with advanced solid tumors. Mol Cancer Ther 2011; 10 (Suppl. 1); abstract B243
32. Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: A nonrandomised, open-label phase 2 study. Lancet Oncol 2013; 14:249-256
33. Johnston S. XL518, a potent selective orally bioavailable MEK1 inhibitor, downregulates the RAS/RAF/MEK/ERK pathway in vivo, resulting in tumor growth inhibition and regression in preclinical models. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 2007; San Francisco, California, USA
34. LoRusso P, Shapiro G, Pandya SS, et al. A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors. J Clin Oncol, ASCO Meeting Abstracts 2012; 30 (15 Suppl.); abstract 2566
35. Kim K, Kong SY, Fulciniti M, et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic antimyeloma activity in vitro and in vivo. Br J Haematol 2010; 149:537-549
36. Yoon J, Koo KH, Choi KY. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res 2011; 71:445-453
37. Massimini G, Laffranchi B, Rejeb N, et al. Selection of indications for pimasertib in phase II testing based on signals of activity and rational choice of target disease. Ann Oncol 2013; 24 (Suppl. 1):i33-i35
38. Byron SA, Loch DC, Wellens CL, et al. Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wild-Type PTEN status. Mol Cancer 2012; 11:75
39. Borad MJ, Akerele CE, Ramanathan RK, et al. Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors. J Clin Oncol 2010; 28 (15(Suppl.)); abstract 2505
40. Dong Q, Dougan DR, Gong X, et al. Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer. Bioorg Med Chem Lett 2011; 21:1315-1319
41. Von Euw E, Atefi M, Attar N, et al. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer 2012; 11:22
42. Isshiki Y, Kohchi Y, Iikura H, et al. Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent. Bioorg Med Chem Lett 2011; 21:1795-1801
43. Leijen S, Middleton MR, Tresca P, et al. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Clin Cancer Res 2012; 18:4794-4805
44. Ishii N, Harada N, Joseph EW, et al. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer Res 2013; 73:4050-4060
45. Martinez-Garcia M, Banerji U, Albanell J, et al. First-in-human, phase I dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin Cancer Res 2012; 18:4806-4819
46. Paraiso KH, Fedorenko IV, Cantini LP, et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 2010; 102:1724-1730
47. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366:207-215
48. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367:1694-1703
49. McArthur G, Gonzalez R, Pavlick A, et al. Vemurafenib (VEM) and MEK inhibitor, cobimetinib (GDC0973), in advanced BRAF V600-mutated melanoma (BRIM-7): Dose-escalation and expansion results of a phase Ib study. Eur J Cancer 2013; 49 (Suppl. 2); abstract 3703
50. Kefford R, Miller WH, Shao-Weng Tan D, et al. Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors. J Clin Oncol 2013; 31 (Suppl.): Abstract 9029
51. McCubrey JA, May WS, Duronio V, Mufson A. Serine/threonine phosphorylation in cytokine signal transduction. Leukemia 2000; 14:9-21
52. Chang F, Steelman LS, Shelton JG, et al. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway. Int J Oncol 2003; 22:469-480
53. Shindo T, Kim TK, Benjamin CL, et al. MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner. Blood 2013; 121:4617-4626
54. Terai M, Eto M, Young GD, et al. Interleukin 6 mediates production of interleukin 10 in metastatic melanoma. Cancer Immunol Immunother 2012; 61:145-155
55. Callahan M. Defining the effects of MAPK pathway inhibition in human immune cells. Perspectives in melanoma XV; 16-17 September 2011. New York, New York, USA
56. Ott PA, Henry T, Baranda SJ, et al. Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. Cancer Immunol Immunother 2013; 62:811-822